Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Investing.com - Canaccord Genuity raised its price target on AtriCure Inc. (NASDAQ:ATRC) to $64.00 from $53.00 on Thursday, while maintaining a Buy rating following the company’s third-quarter earnings report. According to InvestingPro data, analysts remain broadly positive on AtriCure , with a consensus "Strong Buy" recommendation and price targets ranging from $40 to $60.
AtriCure reported Q3/25 revenue of $134.3 million, representing 15.1% year-over-year growth on a constant currency basis. This performance exceeded both Canaccord’s estimate of $131.6 million and the consensus forecast of $131.3 million. The strong quarterly results align with the company’s overall revenue growth of 16.28% over the last twelve months.
The medical device company posted adjusted EBITDA of $17.8 million, significantly outperforming Canaccord’s projection of $13.3 million and consensus estimates of $11.7 million. The firm noted AtriCure continues to deliver strong gross margins and solid SG&A leverage.
According to Canaccord Genuity, the quarterly beat was driven by continued growth in AtriCure’s EnCompass and AtriClip product lines. The company has raised its revenue guidance following these results, which Canaccord believes reflects the conservative nature of AtriCure’s projections. This positive outlook is supported by InvestingPro data showing six analysts have recently revised their earnings forecasts upward for the upcoming period.
AtriCure also increased its adjusted EBITDA guidance while signaling ongoing investment in R&D initiatives, including the start of the BoxX-NoAF trial and continued follow-up on LeAAPS.
In other recent news, AtriCure Inc. reported its third-quarter 2025 financial results, surpassing analyst expectations in multiple areas. The company’s revenue reached $134.3 million, exceeding the forecast of $131.25 million, and earnings per share came in at -$0.01, significantly better than the predicted -$0.11. This performance led AtriCure to raise its full-year 2025 guidance across revenue, EBITDA, and earnings per share. Furthermore, the company experienced a 16% year-over-year revenue growth, with adjusted EBITDA more than doubling to $17.8 million, surpassing Street expectations of $11.7 million.
Following these results, Needham maintained its Buy rating for AtriCure with a price target of $45.00, while Citizens reiterated its Market Outperform rating and set a price target of $60.00. Despite the positive earnings report, AtriCure’s stock experienced a slight dip in after-hours trading. These developments highlight the company’s strong performance in the third quarter and the positive outlook from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.